Human Life CORD
Tokyo, Japan· Est.
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $3.6B
AI Company Overview
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
ImmunologyRespiratoryHematologyAutoimmune
Technology Platform
Platform for sourcing, storing, and developing therapies from umbilical cord-derived mesenchymal stromal cells (UC-MSCs), transforming umbilical cord tissue into standardized therapeutic products.
Opportunities
Expansion into global markets through their global strategy team and potential label expansion of HLC-001 into additional inflammatory and autoimmune conditions represents significant growth potential.
Risk Factors
Clinical trial risks for their Phase 3 NIPCs program, regulatory hurdles for cell therapy approvals, and dependence on partner Mochida Pharmaceutical for commercialization of lead programs.
Competitive Landscape
Competes with other MSC therapy developers like Mesoblast and domestic Japanese regenerative medicine companies; differentiation lies in their specific focus on umbilical cord-derived MSCs and strategic partnerships with established pharma companies.